48
Participants
Start Date
August 31, 2007
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
Pemetrexed and Gemcitabine plus Bevacizumab
Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m\^2 and gemcitabine 1500 mg/m\^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
Pennsylvania Oncology Hematology Associates, Philadelphia
Cancer Specialists of Tidewater, Chesapeake
Northwest Georgia Oncology Center, Marietta
Augusta Oncology Associates, Augusta
Central Georgia Cancer Care, Macon
The West Clinic, Memphis
Tri-County Oncology Hematology Associates, Canton
Hematology Oncology Centers of the Northern Rockies, Billings
Pacific Oncology, PC, Portland
Medical Oncology & Hematology, Waterbury
Collaborators (1)
Eli Lilly and Company
INDUSTRY
Genentech, Inc.
INDUSTRY
Accelerated Community Oncology Research Network
OTHER